Skeletal langerhans cell histiocytosis in children: Permanent consequences and health-related quality of life in long-term survivors

Pediatric Blood and Cancer

Volumn 50, Issue 3, 2008, Pages 607-612

  Lau, Loretta M S ^a   Stuurman, Kyra ^a   Weitzman, Sheila ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bone; Langerhans cell histiocytosis; Permanent consequences; Quality of life

Indexed keywords

ARTICLE; BONE DISEASE; CHILD; DIABETES INSIPIDUS; FEMALE; FOLLOW UP; HISTIOCYTOSIS X; HUMAN; LANGERHANS CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVOR;

ADOLESCENT; BONE DISEASES; CHILD; DIABETES INSIPIDUS, NEUROGENIC; EMOTIONS; ESTHETICS; FEMALE; FOLLOW-UP STUDIES; GROWTH DISORDERS; HEARING LOSS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LEARNING DISORDERS; MALE; ONTARIO; ORGAN SPECIFICITY; PSYCHOLOGY; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVORS;

EID: 38549159970     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21322     Document Type: Article

References (27)

1. Leonidas JC, Guelfguat M, Valderrama E. Langerhans' cell histiocytosis. Lancet 2003;361:1293-1295.
2. Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol 2001;37:108-114.
3. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994;23:72-80.
4. Ceci A, de Terlizzi M, Colella R, et al. Langerhans cell histiocytosis in childhood: Results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol 1993;21:259-264.
5. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 2004;42:438-444.
6. Bernstrand C, Sandstedt B, Ahstrom L, et al. Long-term follow-up of Langerhans cell histiocytosis: 39 years' experience at a single centre. Acta Paediatr 2005;94:1073-1084.
7. Willis B, Ablin A, Weinberg V, et al. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-year experience at the University of California, San Francisco. J Clin Oncol 1996;14:2073-2082.
8. Nanduri VR, Bareille P, Pritchard J, et al. Growth and endocrine disorders in multisystem Langerhans' cell histiocytosis. Clin Endocrinol (Oxf) 2000;53:509-515.
9. Grois NG, Favara BE, Mostbeck GH, et al. Central nervous system disease in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:287-305.
10. Nanduri VR, Lillywhite L, Chapman C, et al. Cognitive outcome of long-term survivors of multisystem langerhans cell histiocytosis: A single-institution, cross-sectional study. J Clin Oncol 2003;21:2961-2967.
11. Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric population health measure: Feasibility, reliability, and validity. Ambul Pediatr 2003;3:329-341.
12. Hopman WM, Towheed T, Anastassiades T, et al. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ 2000;163:265-271.
13. Ware JE Jr, Kosinski M, Gandek B. Reliability, precision, and data quality. In: SF-36 health survey: Manual & interpretation guide. Lincoln: Quality Metric Inc. 2000. pp 7-12.
14. Kusumakumary P, James FV. Permanent disabilities in childhood survivors of Langerhans cell histiocytosis. Pediatr Hematol Oncol 2000;17:375-381.
15. Komp DM, El Mahdi A, Starling KA, et al. Quality of survival in histiocytosis X: A Southwest Oncology Group study. Med Pediatr Oncol 1980;8:35-40.
16. Simms S, Warner NJ. A framework for understanding and responding to the psychosocial needs of children with Langerhans cell histiocytosis and their families. Hematol Oncol Clin North Am 1998;12:359-367.
17. The French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis: 348 cases observed between 1983 and 1993. Arch Dis Child 1996;75:17-24.
18. Whitsett SF, Kneppers K, Coppes MJ, et al. Neuropsychologic deficits in children with Langerhans cell histiocytosis. Med Pediatr Oncol 1999;33:486-492.
19. Bernstrand C, Cederlund K, Sandstedt B, et al. Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Med Pediatr Oncol 2001;36:459-468.
20. Odame I, Li P, Lau L, et al. Pulmonary Langerhans cell histiocytosis: A variable disease in childhood. Pediatr Blood Cancer 2006;47:889-893.
21. Lau L, Krafchik B, Trebo MM, et al. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer 2006;46:66-71.
22. Varni JW, Seid M, Kurtin PS. PedsQL 4.0; Reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001;39:800-812.
23. Varni JW, Burwinkle TM, Rapoff MA, et al. The PedsQL in pediatric asthma: Reliability and validity of the Pediatric Quality of Life Inventory generic core scales and asthma module. J Behav Med 2004;27:297-318.
24. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263.
25. McHorney CA, Ware JE Jr, Lu JF, et al. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
26. Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status: Reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. J Clin Epidemiol 1997;50:79-93.
27. Rosnow RL, Rosenthal R, Rubin DB. Contrasts and correlations in effect-size estimation. Psychol Sci 2000;11:446-453.